BAC
Bank of America Corporation
BAC has the edge over CNO overall, supported by stronger valuation and stronger fundamentals.
CNO
CNO Financial Group, Inc.
CNO has slightly lower modeled downside risk, despite its lower overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CNO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CNO's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNO.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over CNO in the historical PE scenario, which offers more potential upside but is not a forecast.
CNO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $28.30 | -51% |
| Fair | 9.1x | $39.72 | -31% |
| Forward | 11x | $57.44 | — |
| Current | 13x | $57.44 | — |
| Expensive | 15x | $66.35 | +16% |
Historical ranges are pointers, not guarantees.
CNO's PE is in its expensive range at 13x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its fair range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CNO on the outlook, with more favorable revenue expectations.
CNO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNO's earnings to grow and its profitability to improve, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CNO on earnings, with more consistent year-over-year improvement.
CNO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.03 | +15% |
| Q3 2026 | $4.38 | +53% |
| Q2 2026 | $2.91 | +7.4% |
| Q1 2026 | $2.49 | -13% |
| Q4 2025 | $2.23 | -40% |
| Q3 2025 | $2.86 | +15% |
| Q2 2025 | $2.71 | -30% |
| Q1 2025 | $2.86 | -17% |
| Q4 2024 | $3.74 | +55% |
CNO earned $4.38 per share over the past year, up 53% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over CNO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over CNO on profitability, with a higher operating margin.
CNO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | -8.6% |
| Q2 2026 | $1.3B | +12% |
| Q1 2026 | $1B | +2.5% |
| Q4 2025 | $1.1B | +4.2% |
| Q3 2025 | $1.2B | +5.2% |
| Q2 2025 | $1.2B | +8% |
| Q1 2025 | $1B | -13% |
| Q4 2024 | $1.1B | -6.3% |
CNO's revenue grew through 2024 and has held roughly level since: $1.1B last quarter, down 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +6.6 points |
| Q2 2026 | 12% | +2 points |
| Q1 2026 | 13% | +2.2 points |
| Q4 2025 | 15% | -0.7 points |
| Q3 2025 | 14% | +0.1 points |
| Q2 2025 | 9.8% | -4.2 points |
| Q1 2025 | 10% | +4 points |
| Q4 2024 | 16% | +1.2 points |
CNO's operating margin was 20% last quarter, up 6.6 points from the same quarter a year ago, near the top of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
CNO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $242M | +22% |
| Q2 2026 | $156.6M | +7.6% |
| Q1 2026 | $148.8M | +8.9% |
| Q4 2025 | $195.7M | +2.5% |
| Q3 2025 | $197.8M | -14% |
| Q2 2025 | $145.5M | +31% |
| Q1 2025 | $136.7M | +45% |
| Q4 2024 | $191M | +8.1% |
CNO has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CNO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CNO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -699K shares |
| 1 year | -4.4% | -4.3M shares |
| 3 years | -18% | -20.2M shares |
| 5 years | -27% | -34.8M shares |
| Available history | -40% | -62.9M shares |
CNO has 94M diluted shares, down 4.4% from a year ago, with $254M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $59.5M |
| Q2 2026 | $60.9M |
| Q1 2026 | $73.3M |
| Q4 2025 | $60.2M |
| Q3 2025 | $60.6M |
| Q2 2025 | $100.3M |
| Q1 2025 | $110.3M |
| Q4 2024 | $91.7M |
CNO spent $254M buying back its own shares over the past year, down 30% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CNO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -2.4x | Net Cash |
CNO has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CNO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 74.8 | Neutral |
CNO's weekly RSI is 63 (neutral) and its Stochastic is 75 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over CNO on valuation relative to its sector.
CNO PE vs Financial Services Sector
| Metric | CNO | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.7% above |
| PE % | 72 | 63 | 9 pts above |
CNO is trading at 13x earnings, in line with the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CNO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $55.0 | 4.5% above |
| 20 week MA | $54.6 | 5.2% above |
| 50 week MA | $48.1 | 19% above |
| 100 week MA | $43.5 | 32% above |
| 200 week MA | $35.4 | 62% above |
CNO has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
CNO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $22.8 | +25% |
| 2021 | $22.8 | $24.0 | +5% |
| 2022 | $24.0 | $22.9 | -4.6% |
| 2023 | $22.9 | $27.9 | +22% |
| 2024 | $27.9 | $37.3 | +34% |
| 2025 | $37.3 | $43.3 | +16% |
| 2026 YTD | $43.3 | $57.4 | +33% |
CNO has the edge over BAC on returns for 2026, with the stronger performance.